Citi analyst Patrick Donnelly raised the firm’s price target on Hologic to $85 from $75 and keeps a Neutral rating on the shares following the fiscal Q1 results. The beat was broad based with COVID revenue of $164M well ahead of guidance of $110M, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HOLX: